Attorney General Kathy Jennings is calling on consumers to assess their eligibility for compensation related to certain generic drug purchases. Delaware, along with 50 states and territories, is seeking preliminary approval of a $39.1 million settlement with generic drug manufacturer Apotex. The settlement addresses allegations of price inflation and competition limitation by the company.
"Delawareans may qualify for restitution under the terms of this multimillion-dollar pharmaceutical settlement," stated AG Jennings. "I urge all consumers and patients to review their rights under this settlement and to act now to claim money that they may be entitled to."
The settlement with Apotex was reached in principle last fall, alongside a $10 million settlement with Heritage Pharmaceuticals. The settlement's finalization was initially dependent on the signatures of all involved states and territories. With the required signatures now acquired, the coalition is filing the settlement in a federal court in Connecticut.
Consumers who purchased specified generic prescription drugs between May 2009 and December 2019 might qualify for compensation. To verify eligibility, individuals can call 1-866-290-0182, email info@AGGenericDrugs.com, or visit www.AGGenericDrugs.com.
The settlements address claims that Apotex and Heritage engaged in extensive conspiracies to inflate and manipulate drug prices, decrease competition, and restrain trade unreasonably. As part of the agreement, both companies will cooperate in ongoing multistate litigations against 30 corporate defendants and 25 individual executives. Additionally, Apotex and Heritage have committed to implementing internal reforms to promote fair competition and adhere to antitrust laws.